Therapeutic Peptides in 2026: This Year's Breakthroughs

Peptides — amino-acid chains larger than a small molecule but smaller than an antibody — have been used as drugs for decades. What makes 2026 worth isolating is the density of concrete results in a single year, most of them in metabolic disease and oncology, the two areas where more than 1,200 peptides are now reported to be in clinical development (Nature, Signal Transduction and Targeted Therapy, 2024). Four specific things moved this year.

1. Efficacy reached a new high in late-stage data

The incretin line had already climbed from one receptor to several: tirzepatide (GIP + GLP-1) produced up to roughly 21% mean weight loss at 72 weeks in SURMOUNT-1 (NEJM, 2022), and the triple agonist retatrutide (GIP + GLP-1 + glucagon) produced 24.2% at 48 weeks in phase 2 (NEJM, 2023).

In May 2026, Eli Lilly reported the first phase 3 readout for retatrutide. In TRIUMPH-1 (2,339 participants), mean weight reduction at 80 weeks was 17.6%, 23.7%, and 25.0% at the 4-, 9-, and 12-mg doses, versus 3.9% with placebo; in a subset with BMI ≥35 who tolerated escalation to the maximum dose, reductions reached about 30% at 104 weeks. Discontinuations due to adverse events were 4.1%, 6.9%, and 11.3% across the three doses versus 4.9% with placebo (Eli Lilly, 2026; AJMC, 2026). Readouts from TRIUMPH-2 (with type 2 diabetes) and TRIUMPH-3 (with established cardiovascular disease) are expected later in 2026.

2. The obesity field moved beyond the incretins, to amylin

The newer 2025–2026 story is a different hormone pathway. Amylin-receptor activation reduces body weight through a satiety mechanism distinct from the incretins, and the class advanced on its own this year rather than as another GLP-1 variant.

On 5 March 2026, Roche/Genentech announced positive phase 2 results for petrelintide, a long-acting amylin analogue given once weekly: in ZUPREME-1 (493 participants) it produced up to 10.7% mean weight loss at week 42 versus 1.7% with placebo, with what the company described as placebo-like gastrointestinal tolerability — no vomiting at the maximally effective dose and no discontinuations from gastrointestinal events — and a phase 3 start expected later in 2026 (Roche, 2026). Separately, Eli Lilly's selective amylin agonist eloralintide produced mean reductions up to 20.1% at 48 weeks versus 0.4% with placebo in a 263-patient phase 2 trial, with mild-to-moderate nausea and fatigue as the common adverse events (The Lancet, 2025).

The combination approach also reached regulators. CagriSema pairs the amylin analogue cagrilintide with semaglutide; it produced a 22.7% mean reduction at 68 weeks in the REDEFINE 1 phase 3 trial (NEJM, 2025), and Novo Nordisk submitted it to the FDA in December 2025 with a decision expected around October 2026 (Novo Nordisk, 2025).

3. New routes and formats: oral for obesity, and a monthly conjugate

Peptides have historically been injectables, because the gut degrades them and oral bioavailability sat below roughly 1%. Two structural changes are now in the market or close to it.

On 22 December 2025 the U.S. FDA approved the oral Wegovy pill — once-daily oral semaglutide 25 mg, formulated with the absorption enhancer SNAC — for chronic weight management and cardiovascular risk reduction, the first oral GLP-1 cleared for weight management, with a U.S. launch in early January 2026; in the OASIS 4 trial it produced 16.6% mean weight loss when adhered to (Novo Nordisk, 2025; AJMC, 2025). On the format side, maridebart cafraglutide (MariTide) is a peptide–antibody conjugate — an anti-GIP-receptor antibody linked to two GLP-1 agonist peptides — whose antibody scaffold enables once-monthly subcutaneous dosing; its phase 2 trial reported up to about 20% mean weight loss (NEJM, 2025), and phase 3 is underway.

4. Beyond metabolism: peptide-guided radioligand therapy keeps advancing

Outside obesity, the active peptide frontier is oncology, where the peptide is a targeting ligand that carries a radioactive isotope to tumor cells. Two agents established the approach — ¹⁷⁷Lu-DOTATATE in neuroendocrine tumors (NETTER-1: 65% vs 11% progression-free survival at 20 months, NEJM 2017) and ¹⁷⁷Lu-PSMA-617 in prostate cancer (VISION: 38% lower risk of death, hazard ratio 0.62, NEJM 2021). The pipeline kept moving into 2026: ITM's ¹⁷⁷Lu-edotreotide (ITM-11) for gastroenteropancreatic neuroendocrine tumors carries an FDA decision goal date of 28 August 2026 (McGuireWoods radiopharmaceutical industry update, Q1 2026).

What 2026 shows

The year's results point in one direction: peptide efficacy in obesity reached the high-twenties to about 30% in late-stage data, the mechanism set widened from incretins to amylin and to engineered conjugates, an oral peptide entered weight management, and the oncology radioligand pipeline advanced toward new approvals. The picture is not uniform — adverse-event-driven discontinuations rose at the highest retatrutide dose, CagriSema's results drew mixed reception against expectations, amylin and conjugate agents are mostly mid-stage, and radioligand therapy still depends on receptor expression. These are the documented facts of the year, not projections.

Therapeutic Peptides in 2026: This Year's Breakthroughs

Therapeutic Peptides in 2026: This Year's Breakthroughs

1. Efficacy reached a new high in late-stage data

2. The obesity field moved beyond the incretins, to amylin

3. New routes and formats: oral for obesity, and a monthly conjugate

4. Beyond metabolism: peptide-guided radioligand therapy keeps advancing

What 2026 shows

References

Sourcing or supplying what you just read about?

Related articles

What Are Electronic Resins? The Polymers Inside Chips, Substrates, and Circuit Boards

Asia's Biggest Pharma Show Is Back: A Sourcing Playbook for CPHI & PMEC China 2026

REACH in 2026: Two New SVHCs and a PFAS Foam Deadline Worth Planning For